Chronic hepatitis B viral infection among RA patients—a cross-sectional control study
- 10 Downloads
Background and objectives
Rheumatoid arthritis (RA) is the most common inflammatory joint disorder presenting also with extra-articular manifestations. As many other autoimmune diseases, it has been suggested that infectious diseases might contribute to its emergence. Hepatitis viruses were suggested by several reports as a trigger of RA onset. We aimed to assess the association between RA and chronic hepatitis B viral infection (HBV).
Patients with RA were compared with age- and sex-matched controls regarding the proportion of chronic HBV infection in a case-control study. The chi-square and t tests were used for univariate analysis, whereas a logistic regression model was used for multivariate analysis. The study was performed utilizing the medical database of Clalit Health Services.
There was a significantly higher proportion of chronic HBV infection in RA patients compared with controls (1.19% vs 0.63%, respectively; p < 0.001). In a multivariate logistic regression analysis, RA was significantly associated with chronic HBV infection (OR = 1.89, 95%CI 1.55–2.29, p < 0.001).
Patients with RA have a greater proportion of chronic HBV infection than matched controls. Screening for HBV infection among RA patients may be warranted.
KeywordsAutoimmune disease Autoimmunity Hepatitis B virus Rheumatoid arthritis
Compliance with ethical standards
The study was approved by the ethical committee of CHS, located at the Soroka Medical Center, Beer-Sheva, Israel.
Conflict of interest
Naim Mahroum- no conflict of interests.
Abdulla Watad - no conflict of interests.
Shmuel Tiosano - no conflict of interests.
Ashraf Hejly - no conflict of interests.
Hussein Mahagna - no conflict of interests.
Roy Waknin - no conflict of interests.
Doron Comaneshter - no conflict of interests.
Arnon Cohen received research grants from Janssen, Novartis, AbbVie, and Sanofi. Other relationships: In the last 3 years, Prof. Arnon Cohen served as a consultant, advisor, or speaker to AbbVie; Amgen; Boehringer Ingelheim; Dexcel pharma; Janssen; Kamedis; Lilly; Neopharm; Novartis; Perrigo; Pfizer, Rafa, Sanofi, Sirbal; Taro.
Howard Amital- received research grants from Janssen, Novartis, AbbVie and Pfizer. Other relationships: In the last 3 years Howard Amital served as a consultant, advisor or speaker to AbbVie; Boehringer Ingelheim; Janssen; Neopharm; Novartis; Perrigo; Pfizer, Rafa, Sanofi, Sanofi, Taro, Roche.
- 7.Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, de Bois MH, Breedveld FC, Dijkmans BA, Lems WF (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68(3):330–336. https://doi.org/10.1136/ard.2007.086348 CrossRefGoogle Scholar
- 15.Watad A, Azrielant S, Bragazzi NL, Sharif K, David P, Katz I, Aljadeff G, Quaresma M, Tanay G, Adawi M, Amital H, Shoenfeld Y (2017) Seasonality and autoimmune diseases: the contribution of the four seasons to the mosaic of autoimmunity. J Autoimmun 82:13–30. https://doi.org/10.1016/j.jaut.2017.06.001 CrossRefGoogle Scholar
- 21.World Health Organization (2017) Global Hepatitis Programme. Global hepatitis report, 2017Google Scholar
- 22.Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64(5):625–639CrossRefGoogle Scholar
- 26.Watad A, Tiosano S, Azrielant S, Whitby A, Comaneshter D, Cohen AD, Shoenfeld Y, Amital H (2017) Low levels of calcium or vitamin D - which is more important in systemic lupus erythematosus patients? An extensive data analysis. Clin Exp Rheumatol 35(1):108–112Google Scholar
- 27.Watad A, Tiosano S, Yahav D, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H (2017) Behcet’s disease and familial Mediterranean fever: two sides of the same coin or just an association? A cross-sectional study. Eur J Intern Med 39:75–78. https://doi.org/10.1016/j.ejim.2016.10.011 CrossRefGoogle Scholar
- 30.Wilder RL, Crofford LJ (1991) Do infectious agents cause rheumatoid arthritis? Clin Orthop Relat Res (265):36–41Google Scholar
- 33.Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, Ghogomu ET, Coyle D, Clifford T, Tugwell P, Wells GA (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386(9990):258–265. https://doi.org/10.1016/s0140-6736(14)61704-9 CrossRefGoogle Scholar
- 37.Lin TC, Hashemi N, Kim SC, Yang YK, Yoshida K, Tedeschi S, Desai R, Solomon DH (2018) Practice pattern of hepatitis B testing in rheumatoid arthritis patients: a cross-national comparison between the US and Taiwan. Arthritis Care Res (Hoboken) 70(1):30–38. https://doi.org/10.1002/acr.23241 CrossRefGoogle Scholar
- 39.Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M (2011) Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 46(4):556–564CrossRefGoogle Scholar